Format

Send to

Choose Destination
Cytotherapy. 2019 Jun 10. pii: S1465-3249(19)30387-1. doi: 10.1016/j.jcyt.2019.04.002. [Epub ahead of print]

Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon.

Author information

1
Hybrid Concepts International (HCI), LLC; Alliance for Regenerative Medicine (ARM) Science & Technology Committee; Standards Coordinating Body for Gene, Cell, and Regenerative Medicines and Cell-based Drug Discovery (SCB); International Society for Cell & Gene Therapy North American Legal & Regulatory Affairs Committee. Electronic address: Dr_Mike@OurHybridConcepts.com.
2
A2Z Reg Solutions, LLC; International Society for Cell & Gene Therapy North American Legal & Regulatory Affairs Committee.
3
Chimera TQM LLC.
4
Cell Medica, Inc.; International Society for Cell & Gene Therapy North American Legal & Regulatory Affairs Committee.
5
Magenta Therapeutics, Inc.; International Society for Cell & Gene Therapy North American Legal & Regulatory Affairs Committee.

Abstract

Cellular & Gene Therapies (CGTs) are complex products, which have been key foci of the International Society for Cell & Gene Therapy (ISCT). For this ISCT North American Legal & Regulatory Affairs Committee review publication, CGTs include but are not limited to somatic cell-based therapies, pluripotent cell-derived cell-based therapies, gene- or non-gene-modified or gene edited versions of these cell-based therapies, in vivo gene therapies, organ/tissue engineered products, and relevant combination products. These products are regulated by the Food and Drug Administration (FDA) in the United States. This publication reviews selected laws, regulations, guidance, definitions, processes, types of meetings and submissions, and other key factors that the FDA follows and implements to regulate and support development of these types of products. These factors may be considered in order to help current and potential product developers/sponsors/applicants navigate through FDA regulatory pathways. We also review expedited programs including types of Designations available at the FDA, and their specific eligibility criteria. We include FDA and other stakeholder resources to consider regarding CGT regulation, to help prepare for CGT development and subsequent FDA approval.

PMID:
31196820
DOI:
10.1016/j.jcyt.2019.04.002

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center